دورية أكاديمية
أعرض في EDS

Compromised Myelin and Axonal Molecular Organization Following Adult-Onset Sulfatide Depletion.

التفاصيل البيبلوغرافية
العنوان: Compromised Myelin and Axonal Molecular Organization Following Adult-Onset Sulfatide Depletion.
المؤلفون: Dustin E; Research Service, Richmond Veterans Affairs Medical Center, Central Virginia Veterans Affairs Health Care System, Richmond, VA 23249, USA.; Department of Anatomy and Neurobiology, Virginia Commonwealth University, Richmond VA 23298, USA., Suarez-Pozos E; Research Service, Richmond Veterans Affairs Medical Center, Central Virginia Veterans Affairs Health Care System, Richmond, VA 23249, USA.; Department of Anatomy and Neurobiology, Virginia Commonwealth University, Richmond VA 23298, USA., Stotesberry C; Department of Biology, Virginia Commonwealth University, Richmond, VA 23298, USA., Qiu S; Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA., Palavicini JP; Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA., Han X; Sam and Ann Barshop Institute for Longevity and Aging Studies, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.; Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA., Dupree JL; Research Service, Richmond Veterans Affairs Medical Center, Central Virginia Veterans Affairs Health Care System, Richmond, VA 23249, USA.; Department of Anatomy and Neurobiology, Virginia Commonwealth University, Richmond VA 23298, USA.
المصدر: Biomedicines [Biomedicines] 2023 May 12; Vol. 11 (5). Date of Electronic Publication: 2023 May 12.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101691304 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9059 (Print) Linking ISSN: 22279059 NLM ISO Abbreviation: Biomedicines Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: 3-O-sulfogalactosylceramide, or sulfatide, is a prominent myelin glycosphingolipid reduced in the normal appearing white matter (NAWM) in Multiple Sclerosis (MS), indicating that sulfatide reduction precedes demyelination. Using a mouse model that is constitutively depleted of sulfatide, we previously demonstrated that sulfatide is essential during development for the establishment and maintenance of myelin and axonal integrity and for the stable tethering of certain myelin proteins in the sheath. Here, using an adult-onset depletion model of sulfatide, we employ a combination of ultrastructural, immunohistochemical and biochemical approaches to analyze the consequence of sulfatide depletion from the adult CNS. Our findings show a progressive loss of axonal protein domain organization, which is accompanied by axonal degeneration, with myelin sparing. Similar to our previous work, we also observe differential myelin protein anchoring stabilities that are both sulfatide dependent and independent. Most notably, stable anchoring of neurofascin155, a myelin paranodal protein that binds the axonal paranodal complex of contactin/Caspr1, requires sulfatide. Together, our findings show that adult-onset sulfatide depletion, independent of demyelination, is sufficient to trigger progressive axonal degeneration. Although the pathologic mechanism is unknown, we propose that sulfatide is required for maintaining myelin organization and subsequent myelin-axon interactions and disruptions in these interactions results in compromised axon structure and function.
References: J Neurochem. 2018 Dec;147(6):712-714. (PMID: 30474166)
Genesis. 2003 Jan;35(1):63-72. (PMID: 12481300)
Brain. 2006 Dec;129(Pt 12):3173-85. (PMID: 17041241)
J Neurocytol. 1999 Apr-May;28(4-5):349-64. (PMID: 10739576)
J Neurosci Res. 1988 Oct-Dec;21(2-4):249-59. (PMID: 2464077)
J Neurochem. 2005 Sep;94(6):1696-710. (PMID: 16045452)
Glia. 2016 Jul;64(7):1190-209. (PMID: 27100937)
Front Cell Dev Biol. 2021 Mar 08;9:653101. (PMID: 33763430)
J Neurosci. 2002 Aug 1;22(15):6507-14. (PMID: 12151530)
Cell Mol Life Sci. 2016 Feb;73(4):723-35. (PMID: 26514731)
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:197-210. (PMID: 12432919)
Neuron. 2003 Oct 9;40(2):297-318. (PMID: 14556710)
Can J Biochem Physiol. 1959 Aug;37(8):911-7. (PMID: 13671378)
Glia. 2006 Nov 1;54(6):499-512. (PMID: 16927294)
J Cell Biol. 2003 Sep 15;162(6):1149-60. (PMID: 12963709)
Chem Phys Lipids. 2018 Nov;216:114-131. (PMID: 30194926)
Glia. 2006 Mar;53(4):372-81. (PMID: 16288467)
Neurochem Res. 2016 Feb;41(1-2):130-43. (PMID: 26542149)
J Lipid Res. 1965 Oct;6(4):537-44. (PMID: 5865382)
Cell Rep. 2017 Jan 10;18(2):314-323. (PMID: 28076777)
Nat Neurosci. 2014 Dec;17(12):1673-81. (PMID: 25362471)
Glia. 2005 Apr 1;50(1):86-90. (PMID: 15657937)
Curr Opin Neurobiol. 2017 Dec;47:104-112. (PMID: 29065345)
J Comp Neurol. 2012 Aug 15;520(12):2774-84. (PMID: 22434587)
Nat Genet. 2003 Mar;33(3):366-74. (PMID: 12590258)
J Neurosci. 1997 Nov 1;17(21):8246-58. (PMID: 9334400)
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4227-32. (PMID: 11917099)
Cell Mol Life Sci. 2016 Sep;73(17):3291-310. (PMID: 27141942)
Brain Pathol. 2007 Apr;17(2):230-42. (PMID: 17388954)
Glia. 2016 May;64(5):840-52. (PMID: 26840208)
Elife. 2017 Jan 28;6:. (PMID: 28130923)
J Neurosci. 2018 Jul 4;38(27):6063-6075. (PMID: 29853631)
J Neurosci Res. 2009 Jun;87(8):1773-93. (PMID: 19185024)
Langmuir. 2017 Jul 25;33(29):7312-7321. (PMID: 28474888)
J Neurocytol. 1999 Apr-May;28(4-5):281-93. (PMID: 10739571)
J Mol Neurosci. 2008 May;35(1):35-53. (PMID: 18172773)
J Neurosci. 2004 Mar 31;24(13):3176-85. (PMID: 15056697)
J Neuroimmunol. 2018 Sep 15;322:9-14. (PMID: 29803554)
J Cell Biol. 2000 Aug 7;150(3):657-66. (PMID: 10931875)
J Lipid Res. 2020 May;61(5):636-654. (PMID: 31871065)
Physiol Rev. 2019 Jul 1;99(3):1381-1431. (PMID: 31066630)
Neuropathol Appl Neurobiol. 2001 Feb;27(1):50-8. (PMID: 11299002)
Cell. 1992 Feb 7;68(3):533-44. (PMID: 1531449)
J Comp Neurol. 2010 Jul 15;518(14):2841-53. (PMID: 20506478)
J Cell Biol. 2003 Sep 15;162(6):1161-72. (PMID: 12975355)
J Neurochem. 1989 Jan;52(1):296-304. (PMID: 2462020)
Prostaglandins Other Lipid Mediat. 2010 Apr;91(3-4):118-29. (PMID: 19379822)
Biophys J. 1978 Feb;21(2):147-60. (PMID: 623863)
AJNR Am J Neuroradiol. 2019 Nov;40(11):1871-1877. (PMID: 31694819)
Glia. 2008 Jan 1;56(1):118-33. (PMID: 17963267)
Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):814-8. (PMID: 8570640)
Nat Rev Neurol. 2020 Aug;16(8):426-439. (PMID: 32651566)
Brain. 1969;92(3):639-46. (PMID: 5806128)
J Neurosci. 1988 Aug;8(8):3057-66. (PMID: 2842470)
J Neurosci Res. 1989 Apr;22(4):439-48. (PMID: 2474666)
J Neuroinflammation. 2017 Jun 8;14(1):116. (PMID: 28595650)
J Neurocytol. 1998 Sep;27(9):649-59. (PMID: 10447239)
J Neurosci. 2002 Apr 15;22(8):3016-24. (PMID: 11943804)
J Neurosci. 2014 Apr 9;34(15):5089-98. (PMID: 24719088)
Nat Commun. 2016 Dec 06;7:13584. (PMID: 27922006)
J Neurosci Res. 1989 Oct;24(2):201-11. (PMID: 2479763)
Neurochem Res. 2013 Dec;38(12):2490-502. (PMID: 24081651)
Adv Exp Med Biol. 2023 Jan 18;:. (PMID: 36648750)
J Biol Chem. 2002 Feb 8;277(6):4551-7. (PMID: 11733523)
Biochim Biophys Acta Biomembr. 2020 May 1;1862(5):183211. (PMID: 32032590)
Glia. 2013 Apr;61(4):466-74. (PMID: 23322453)
Front Chem. 2023 Feb 21;10:1041961. (PMID: 36896314)
Proc Natl Acad Sci U S A. 2023 Mar 7;120(10):e2207461120. (PMID: 36848577)
J Neurochem. 2002 Jun;81(5):993-1004. (PMID: 12065611)
J Biol Chem. 1996 Nov 15;271(46):29216-22. (PMID: 8910580)
J Neurochem. 1988 Sep;51(3):859-68. (PMID: 2842456)
J Neurosci. 2008 Sep 24;28(39):9741-54. (PMID: 18815260)
Neuron. 2013 May 8;78(3):469-82. (PMID: 23664614)
Nature. 2012 Jul 26;487(7408):443-8. (PMID: 22801498)
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11807-E11816. (PMID: 30487224)
Curr Biol. 2002 Feb 5;12(3):217-20. (PMID: 11839274)
Neurochem Res. 1994 Jun;19(6):721-8. (PMID: 8065530)
Lab Invest. 1969 May;20(5):444-54. (PMID: 5767418)
Biochim Biophys Acta Biomembr. 2022 Dec 1;1864(12):184036. (PMID: 36055359)
Int J Mol Sci. 2022 Dec 23;24(1):. (PMID: 36613677)
Brain. 2010 Feb;133(Pt 2):389-405. (PMID: 20129933)
Neuron. 2011 Jan 27;69(2):244-57. (PMID: 21262464)
J Neurosci Res. 1991 Nov;30(3):540-4. (PMID: 1666129)
J Cell Biol. 1999 Dec 13;147(6):1145-52. (PMID: 10601330)
Anal Chem. 2021 Jan 19;93(2):1185-1192. (PMID: 33296186)
Glia. 2009 Dec;57(16):1815-24. (PMID: 19459211)
FEBS Lett. 2010 May 3;584(9):1741-7. (PMID: 19822144)
Biochim Biophys Acta. 2014 Mar;1838(3):859-66. (PMID: 24239862)
J Neurosci. 1998 Mar 1;18(5):1642-9. (PMID: 9464989)
Mol Neurodegener. 2021 Sep 15;16(1):64. (PMID: 34526055)
معلومات مُعتمدة: P30 AG013319 United States AG NIA NIH HHS; P30 AG044271 United States AG NIA NIH HHS
فهرسة مساهمة: Keywords: lipid rafts; multiple sclerosis; myelin; sphingolipid; sulfatide
تواريخ الأحداث: Date Created: 20230527 Latest Revision: 20240625
رمز التحديث: 20240625
مُعرف محوري في PubMed: PMC10216104
DOI: 10.3390/biomedicines11051431
PMID: 37239102
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9059
DOI:10.3390/biomedicines11051431